The importance of nonpharmacogenetic factors in endocrine therapy

Colin McCowan, Alastair M. Thompson

    Research output: Contribution to journalReview article

    6 Citations (Scopus)

    Abstract

    Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.

    Original languageEnglish
    Pages (from-to)721-728
    Number of pages8
    JournalPharmacogenomics
    Volume13
    Issue number6
    DOIs
    Publication statusPublished - Apr 2012

    Cite this

    McCowan, Colin ; Thompson, Alastair M. / The importance of nonpharmacogenetic factors in endocrine therapy. In: Pharmacogenomics. 2012 ; Vol. 13, No. 6. pp. 721-728.
    @article{8b8f910276e942cba262c8cf6616af06,
    title = "The importance of nonpharmacogenetic factors in endocrine therapy",
    abstract = "Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.",
    author = "Colin McCowan and Thompson, {Alastair M.}",
    year = "2012",
    month = "4",
    doi = "10.2217/PGS.12.29",
    language = "English",
    volume = "13",
    pages = "721--728",
    journal = "Pharmacogenomics",
    issn = "1462-2416",
    publisher = "Future Medicine",
    number = "6",

    }

    The importance of nonpharmacogenetic factors in endocrine therapy. / McCowan, Colin; Thompson, Alastair M.

    In: Pharmacogenomics, Vol. 13, No. 6, 04.2012, p. 721-728.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - The importance of nonpharmacogenetic factors in endocrine therapy

    AU - McCowan, Colin

    AU - Thompson, Alastair M.

    PY - 2012/4

    Y1 - 2012/4

    N2 - Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.

    AB - Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.

    U2 - 10.2217/PGS.12.29

    DO - 10.2217/PGS.12.29

    M3 - Review article

    VL - 13

    SP - 721

    EP - 728

    JO - Pharmacogenomics

    JF - Pharmacogenomics

    SN - 1462-2416

    IS - 6

    ER -